Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Optimization of Immunotherapy in Elderly Cancer Patients

Volume 18, Issue 6, 2013, pp. 573-583
DOI: 10.1615/CritRevOncog.2013010591
Get accessGet access

ABSTRACT

Increasing evidence has revealed the incidence of cancer augments with aging, which could be attributed to a multitude of age-associated changes including the dysregulation of the immune system. Although many reports demonstrate the efficacy of cancer immunotherapies in numerous preclinical studies, most experiments have been performed in young animals. Studies from our group and others show that cancer immunotherapy could be ineffective in old mice, even though the same therapeutic treatment works efficiently in young mice. Given that cancer occurs mostly in the elderly, we should take age-associated immune dysregulation into consideration to achieve the effectiveness of immunotherapeutic interventions in the old. Understanding both age-related and tumor-related immune alterations might be equally important in improving the effectiveness of immunotherapy. This article reviews a number of age-associated immune alterations with specific attention given to the impact on antitumor responses, and also discusses possible strategies for optimization of immunotherapeutic interventions in the elderly.

CITED BY
  1. Pitt Jonathan M., Vétizou Marie, Daillère Romain, Roberti María Paula, Yamazaki Takahiro, Routy Bertrand, Lepage Patricia, Boneca Ivo Gomperts, Chamaillard Mathias, Kroemer Guido, Zitvogel Laurence, Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors, Immunity, 44, 6, 2016. Crossref

  2. Micheletti Leonardo, Preti Mario, Radici Gianluigi, Boveri Sara, Di Pumpo Orazio, Privitera Sebastiana S., Ghiringhello Bruno, Benedetto Chiara, Vulvar Lichen Sclerosus and Neoplastic Transformation, Journal of Lower Genital Tract Disease, 20, 2, 2016. Crossref

  3. Bidnur S., Savdie R., Black P.C., Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer, Bladder Cancer, 2, 1, 2016. Crossref

  4. Hartmann Stefan, Grandis Jennifer R., Treatment of head and neck cancer in the elderly, Expert Opinion on Pharmacotherapy, 17, 14, 2016. Crossref

  5. Nishijima Tomohiro F., Muss Hyman B., Shachar Shlomit S., Moschos Stergios J., Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treatment Reviews, 45, 2016. Crossref

  6. Friedman Claire F., Wolchok Jedd D., Checkpoint inhibition and melanoma: Considerations in treating the older adult, Journal of Geriatric Oncology, 8, 4, 2017. Crossref

  7. Marrone Kristen A., Forde Patrick M., Cancer Immunotherapy in Older Patients, The Cancer Journal, 23, 4, 2017. Crossref

  8. Shimabukuro-Vornhagen Alexander, Gödel Philipp, Schlößer Hans Anton, von Bergwelt-Baildon Michael, Zukünftige Entwicklungen in der Immunonkologie, InFo Onkologie, 20, S1, 2017. Crossref

  9. Sgambato Assunta, Casaluce Francesca, Gridelli Cesare, The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly, Expert Opinion on Biological Therapy, 17, 5, 2017. Crossref

  10. Zhao Bin, Zhao Hong, Zhao Jiaxin, Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma, International Journal of Cancer, 144, 1, 2019. Crossref

  11. Belgioia Liliana, Desideri Isacco, Errico Angelo, Franzese Ciro, Daidone Antonino, Marino Lorenza, Fiore Michele, Borghetti Paolo, Greto Daniela, Fiorentino Alba, Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review, Critical Reviews in Oncology/Hematology, 133, 2019. Crossref

  12. Macchini Marina, Chiaravalli Marta, Zanon Silvia, Peretti Umberto, Mazza Elena, Gianni Luca, Reni Michele, Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives, Cancer Treatment Reviews, 72, 2019. Crossref

  13. Quoix Elisabeth, Lung Cancer in Older Adults: Systemic Treatment, in Geriatric Oncology, 2018. Crossref

  14. Harrison Rebecca A., de Groot John F., Treatment of Glioblastoma in the Elderly, Drugs & Aging, 35, 8, 2018. Crossref

  15. Sattar Joobin, Kartolo Adi, Hopman Wilma M., Lakoff Joshua Matthew, Baetz Tara, The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population, Journal of Geriatric Oncology, 10, 3, 2019. Crossref

  16. Marrone Kristen A., Forde Patrick M., Cancer Immunotherapy in Older Patients, The Cancer Journal, 23, 4, 2017. Crossref

  17. Bhandari Shruti, Gill Amitoj S, Perez Cesar A, Jain Dharamvir, Management of immunotherapy toxicities in older adults, Seminars in Oncology, 45, 4, 2018. Crossref

  18. Orloff Marlana, Melanoma Immunotherapy in the Elderly, Current Oncology Reports, 20, 2, 2018. Crossref

  19. Sekido Katsuhisa, Tomihara Kei, Tachinami Hidetake, Heshiki Wataru, Sakurai Kotaro, Moniruzzaman Rohan, Imaue Shuichi, Fujiwara Kumiko, Noguchi Makoto, Alterations in composition of immune cells and impairment of anti-tumor immune response in aged oral cancer-bearing mice, Oral Oncology, 99, 2019. Crossref

  20. Stravinskienė Dovilė, Žvirblienė Aurelija, Development of Therapeutic Antibodies Against Carbonic Anhydrases, in Carbonic Anhydrase as Drug Target, 2019. Crossref

  21. Zhou Alice Y., Wang Daniel Y., McKee Svetlana, Ye Fei, Wen Chun‐Che, Wallace Debbie E., Ancell Kristin K., Conry Robert M., Johnson Douglas B., Correlates of response and outcomes with talimogene laherperpvec, Journal of Surgical Oncology, 120, 3, 2019. Crossref

  22. Perrotta Fabio, Rocco Danilo, Vitiello Fabiana, De Palma Raffaele, Guerra Germano, De Luca Antonio, Navani Neal, Bianco Andrea, Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients, International Journal of Molecular Sciences, 20, 9, 2019. Crossref

  23. Saba Nabil F., Blumenschein George, Guigay Joel, Licitra Lisa, Fayette Jerome, Harrington Kevin J., Kiyota Naomi, Gillison Maura L., Ferris Robert L., Jayaprakash Vijayvel, Li Li, Brossart Peter, Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age, Oral Oncology, 96, 2019. Crossref

  24. Imai Hisao, Wasamoto Satoshi, Yamaguchi Ou, Suzuki Kensuke, Sugiyama Tomohide, Uchino Junji, Minemura Hiroyuki, Osaki Takashi, Ishii Hisashi, Umeda Yukihiro, Mori Keita, Kotake Mie, Kagamu Hiroshi, Morozumi Nobutoshi, Taniguchi Hirokazu, Kasai Takashi, Minato Koichi, Kaira Kyoichi, Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer, Journal of Cancer Research and Clinical Oncology, 146, 2, 2020. Crossref

  25. Zheng S.-Y., Cui H.-J., Duan H., Peng Y.-M., Li Q., Sun C.-Y., Zhang J.-Y., Shen W., Zhang X., Tan K., Jiang X., The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis, Clinical and Translational Oncology, 22, 7, 2020. Crossref

  26. Blagosklonny Mikhail, Gudkov Andrei, Introducing, OncoTarget, Oncotarget, 1, 1, 2010. Crossref

  27. Yamaguchi Ou, Imai Hisao, Minemura Hiroyuki, Suzuki Kensuke, Wasamoto Satoshi, Umeda Yukihiro, Osaki Takashi, Kasahara Norimitsu, Uchino Junji, Sugiyama Tomohide, Ishihara Shinichi, Ishii Hisashi, Naruse Ichiro, Mori Keita, Kotake Mie, Kanazawa Kenya, Minato Koichi, Kagamu Hiroshi, Kaira Kyoichi, Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer, Cancer Chemotherapy and Pharmacology, 85, 4, 2020. Crossref

  28. Quoix Elisabeth, Lung Cancer in Older Adults: Systemic Treatment, in Geriatric Oncology, 2020. Crossref

  29. Marconcini Riccardo, Spagnolo Francesco, Stucci Luigia Stefania, Ribero Simone, Marra Elena, De Rosa Francesco, Picasso Virginia, Di Guardo Lorenza, Cimminiello Carolina, Cavalieri Stefano, Orgiano Laura, Tanda Enrica, Spano Laura, Falcone Alfredo, Queirolo Paola, Current status and perspectives in immunotherapy for metastatic melanoma, Oncotarget, 9, 15, 2018. Crossref

  30. Yang Shengjie, Zhang Wenjie, Chen Qing, Guo Qisen, <p>Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study</p>, Cancer Management and Research, Volume 12, 2020. Crossref

  31. Zhang Ying, Ertl Hildegund CJ, Aging: T cell metabolism within tumors, Aging, 8, 6, 2016. Crossref

  32. Deshpande Ravindra Pramod, Sharma Sambad, Watabe Kounosuke, The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors, Cancers, 12, 10, 2020. Crossref

  33. Huang Xinyi, Tian Tiantian, Zhang Yan, Zhou Shengjian, Hu Pingping, Zhang Jiandong, Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy, Frontiers in Oncology, 11, 2021. Crossref

  34. Tambaro Rosa, Napoli Marilena Di, Pisano Carmela, Cecere Sabrina Chiara, Attademo Laura, Rossetti Sabrina, Feroce Florinda, Setola Sergio, Califano Daniela, Russo Daniela, Spina Anna, Perdonà Sisto, Izzo Alessandro, Pignata Sandro, From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer, Immunotherapy, 13, 1, 2021. Crossref

  35. Huang Xuan-zhang, Gao Peng, Song Yong-xi, Sun Jing-xu, Chen Xiao-wan, Zhao Jun-hua, Wang Zhen-ning, Efficacy of immune checkpoint inhibitors and age in cancer patients, Immunotherapy, 12, 8, 2020. Crossref

  36. Khafaga Asmaa F., Noreldin Ahmed E., Saadeldin Islam M., Role of HSP in the Pathogenesis of Age-Related Inflammatory Diseases, in Heat Shock Proteins in Inflammatory Diseases, 22, 2020. Crossref

  37. Nakajima Yuka, Chamoto Kenji, Oura Takuma, Honjo Tasuku, Critical role of the CD44 low CD62L low CD8 + T cell subset in restoring antitumor immunity in aged mice , Proceedings of the National Academy of Sciences, 118, 23, 2021. Crossref

  38. Yang Zheng, Gong Daoqing, Huang Fei, Sun Yi, Hu Qinming, Epidemiological Characteristics and the Development of Prognostic Nomograms of Patients With HIV-Associated Cutaneous T-Cell Lymphoma, Frontiers in Oncology, 12, 2022. Crossref

  39. Haji-Fatahaliha Mostafa, Hosseini Maryam, Akbarian Asiye, Sadreddini Sanam, Jadidi-Niaragh Farhad, Yousefi Mehdi, CAR-modified T-cell therapy for cancer: an updated review, Artificial Cells, Nanomedicine, and Biotechnology, 44, 6, 2016. Crossref

  40. Poropatich Kate, Fontanarosa Joel, Samant Sandeep, Sosman Jeffrey A., Zhang Bin, Cancer Immunotherapies: Are They as Effective in the Elderly?, Drugs & Aging, 34, 8, 2017. Crossref

  41. Wu Qing, Luo Shuimei, Xie Xianhe, Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?, Journal of Immunotherapy, 45, 7, 2022. Crossref

  42. Song Peng, Zhang Jingcheng, Shang Congcong, Zhang Li, Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors, Scientific Reports, 9, 1, 2019. Crossref

  43. Ishitobi Kazunari, Kotani Hitoshi, Iida Yuichi, Taniura Takahito, Notsu Yoshitomo, Tajima Yoshitsugu, Harada Mamoru, A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice, International Immunopharmacology, 113, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain